Day 2Tuesday, 5 November 2024 - CET/CEST (Cent Europe Summer, GMT+2)

Location: Room K2

As the pharma patent cliff approaches, this panel will explore its impact on the industry, examining future pipelines and emerging partnering opportunities. Join industry leaders to discuss strategies for innovation and collaboration, ensuring sustained growth and advancement in the life science landscape. Discover what lies ahead in this pivotal decade.

Location: Room K2

In an era of rapid scientific progression, Immunology has advanced to be the second-largest segment in the biopharma industry, by sales. Join this session to discover the current state of the field, key drivers behind the growth and delve into significant deals, such as the Morphic and DICE by Eli Lilly. Explore the evolving landscape of licensing and partnering opportunities for novel immunological innovations, and gain insights into emerging trends and prospects in the future.

Location: Room K2

Reimagining medicine, together. Working together, we can reimagine medicine to improve and extend people’s lives.

Location: Room K2

We are an innovative global healthcare company, driven by one purpose: we chase the miracles of science to improve people’s lives. Our teams across the world strive to transform the practice of medicine, turning the impossible into the possible for patients. We provide potentially life-changing treatments and the protection of life-saving vaccines to millions of people, and affordable access to our medicines in some of the world’s poorest countries

Location: Room K2

We aspire to be the premier research-intensive biopharmaceutical company. We’re at the forefront of research to deliver innovative health solutions that advance the prevention and treatment of diseases in people and animals.

Location: Room K2

At Lilly, we take smart risks on bold science to achieve our mission of bringing life-changing medicines to patients. As a community of scientists, we understand the brilliance and dedication this work takes. We also recognize our responsibility as partners to help advance life-changing medicines within our walls and beyond. More than 100 years ago, we pioneered strategic collaborations to scale the bold work of four University of Toronto research scientists to launch the world’s first commercial insulin. We're proud to continue our legacy in collaboration, with ~50% of our new product launches in the last 10 years enabled by external innovation, and over 70 active alliances with the vibrant academic and biotech ecosystem.  We know that every partnership is different - from stage, modality, therapeutic area, and culture. We have the skill, capabilities, and know-how to bring a holistic suite of models to life to continuously meet your needs. Let’s grow together!

Location: Room K2

We strive to improve the health of humans and animals - for generations. We work together with integrity and are guided by a shared purpose that defines who we are and what we do

Location: Room K2

Servier is an independent pharmaceutical company committed to therapeutic progress to serve patient needs. Its unique governance allows Servier to reinvest all its profits to support its development, as well as plan and invest with a long-term view, in line with its vocation. Servier's long-term vision applies to its partnership philosophy. With €5.3Bn of revenue in 2023 across 150 countries worldwide, the Group has a growing presence in the USA and Japan, a strong EU presence and a deep knowledge of emerging countries and China. Servier is very focused on specialty care oncology with a proven expertise of over 60 years in cardiovascular and metabolic diseases. It is developing new therapeutic solutions to serve unmet patient needs. From R&D to commercialization, we have proven experience to help new therapeutic innovations become reality for patients, alone or with partners.

Location: Exhibit Hall Stage

The biotech industry has faced a 60% reduction in clinical trial initiations in 2024 compared to previous years. Despite some recovery, R&D funding is still below 2020/21 levels, and the complexity and costs of R&D continue to rise. Join this session to gain evidence-based insights and hear from leading women in biotech as they:

• Comment on the current macro environmental challenges impacting clinical development
• Discuss innovative strategies to overcome these hurdles
• Share their perspective on how EU biotech organizations can thrive amidst these challenges

Location: Exhibit Hall Stage

We look at how global events, deal making, and regulatory and tech advancements are determining the factors driving or squeezing production, while also finding time to focus on developments within a key area of the industry.

Location: Room K11

From the get-go, start-up and pre-clinical stage biopharmaceutical companies rightfully prioritize the scientific foundation of their invention, then swiftly transitioning towards Clinical Development. The priority is often reserved for securing fast-track, accelerated development pathways and expediting entry into first-in-human studies. Undoubtedly, Clinical Development stands as the key in the drug Information Classification: General development journey, commanding utmost attention: it is the highest risk, highest value creation, highest cost, most challenging, and highly regulated and monitored by Regulators Agencies. However, this pursuit of clinical milestones frequently results in the oversight of Chemistry, Manufacturing, and Controls (CMC) Development. Such neglect stems from underestimating the scope, complexity, timelines, cost, and impact of CMC Development - a prerequisite and indispensable precursor to any Toxicology and Clinical Development. This presentation will cover how to fully integrate CMC Development into the product development lifecycle and how pursuing excellence in CMC development will allow start-up and pre-clinical stage biopharmaceutical companies to realize substantial value.

Location: Exhibit Hall Stage

Join Dr. Michael May, a visionary leader in regenerative medicine, as he explores the vibrant landscape of Canada’s life sciences ecosystem with a special focus on AI and regenerative medicine. This session will showcase Canada’s cutting-edge advancements in cell and gene therapy, powered by its world-renowned AI capabilities and collaborative research and innovation culture.

Dr. May will highlight the pivotal role that CCRM plays in advancing regenerative medicine and catalyzing investment in breakthrough therapies. He will also discuss how AI is revolutionizing drug discovery, diagnostics, and personalized medicine in Canada. Attendees will hear first-hand how Canada’s research institutions, biotech companies, and innovators are collaborating to deliver life-changing therapies and positioning Canada as a global leader in life sciences.

Highlights:

• Gain insights into Canada’s latest innovations in advanced therapy and how they are reshaping healthcare.
• Learn about Canada’s thriving life sciences ecosystem and its unique ability to integrate world-class research, government support, and private-sector collaboration.
• Explore investment opportunities in Canada, including access to cutting-edge technologies, talent, and favorable incentives for businesses looking to expand or invest in the country.
• Hear success stories from companies and investors who have leveraged Canada’s resources to accelerate their growth in the life sciences industry.

This session is a must-attend for companies, investors, and innovators seeking to understand Canada’s competitive edge in life sciences and how they can capitalize on emerging opportunities in AI and regenerative medicine.

Location: Exhibit Hall Stage

This session will explore opportunities for biotech companies to develop and implement Advanced Therapy Medicinal Products (ATMPs) across Europe. Leading experts from key European hubs will discuss their collaborative efforts to enhance the visibility of European ATMP innovation and attract increased funding. By sharing insights and best practices, the session aims to foster a unified approach to addressing challenges in ATMP development, including clinical, financial, and workforce training issues. Attendees will gain a comprehensive understanding of the current landscape and future directions for advancing ATMP development in Europe.

Location: K18

Tempus is a technology company advancing precision medicine through the practical application of artificial intelligence in healthcare. With one of the world’s largest libraries of multimodal data, and an operating system to make that data accessible and useful, Tempus provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics. The goal is for each patient to benefit from the treatment of others who came before by providing physicians with tools that learn as the company gathers more data.

Location: K18

Spirea is a Cambridge University spin-out advancing a pipeline of Antibody Drug Conjugates (ADCs) with a lead programme targeting a tumour marker over-expressed in a number of cancers including triple-negative breast cancer. Spirea's ADCs incorporate a proprietary linker-payload technology which enables the incorporation of diverse drug payloads at drug-to-antibody ratios > 16. This provides for extremely high ADC design and payload flexibility and wide therapeutic index in cancer/oncology. Spirea is interested in collaborating with biotech and pharma companies to incorporate its high drug loading Antibody Drug Conjugate linker technology into new or pre-existing drug programmes.

Location: K18

Etnova Therapeutics Corp. has been conducting research and development on synthetic drug-based anticancer therapies since its founding in 2022. The company currently consists of 13 members, including 3 PhD-level researchers and 7 Master’s-level researchers. All researchers in the company are equipped with the expertise to handle the entire drug discovery process, from identifying new drug libraries, synthesis development, and efficacy evaluation to mechanism of action studies. Guided by the slogan 'A new era of therapeutic advances,' all members are united in striving towards the same goal. Here are the major events in the company's history: • August 2020: Company founded • October 2020: Secured angel investment • March 2022: Secured Series A investment • August 2023: IND approval for Phase 1 clinical trial of major pipeline ETN101 in Korea MFDS • February 2024: First patient enrolled in Phase 1 clinical trial of ETN101 in Korea The key pipeline under development is an oral anticancer drug, ETN101. In August 2023, it received IND approval for Phase 1 clinical trials in Korea, and the trials are now ongoing at four institutions nationwide. As of August 2024, Cohort 3 of the trial is currently in progress. In relation to the above, various indications are being expanded, and 8 national grant projects have been completed or are currently being carried out. As for intellectual property rights, 13 patents have been applied for and registered both domestically and internationally. Etnova Therapeutics completed the Series A investment in 2022 and Bridge investment in 2024, with plans for Series B in 2025. Additionally, we are considering SI/FI investment or licensing out for partnering opportunities. By expanding our pipeline and business internationally, we are strengthening our research capabilities and developing additional platform technologies. Etnova Therapeutics will usher in a new era of therapeutic development with a powerful leap forward.

Location: K18

Tenboron is a clinical stage biopharmaceutical company developing superior boron carriers for Boron Neutron Capture Therapy (BNCT) of cancers. BNCT is biochemically targeted radiation therapy especially suitable for treatment of non-resectable or recurrent tumors in the head and neck region. BNCT relies on efficient delivery of boron-10 atoms to cancer cells. When low energy neutron radiation is applied, the boron will react inside the cancer cells destroying them but sparing the surrounding healthy cells. BNCT has many advantages over conventional radiotherapy, but the adoption of this treatment modality has been handicapped by suboptimal carriers and lack of neutron sources. This is now changing as the construction of several new accelerator-based neutron sources is ongoing globally.

Location: K18

Osmol is a clinical stage biopharma company developing a first-in-class preventative treatment for chemotherapy-induced peripheral neuropathy (CIPN). CIPN is a significant unmet need associated with microtubule-based chemotherapies such as taxanes, the most widely used breast cancer chemotherapy treatment. CIPN can be both debilitating and effect cancer treatment outcomes. There are no approved treatments for CIPN, leaving patients’ only option to reduce the dose or length of chemotherapy treatment. Osmol’s initial focus is in breast cancer where up to 80% of taxane treated patients develop CIPN and 50% have their dose or length of treatment adjusted. , CIPN is driven by the dysregulation of neuronal calcium sensor-1 (NCS1). Osmol is developing a first-in-class, patented drug (OSM-0205) to modulate NCS1 function to prevent neuronal damage caused by the off-target effects of chemotherapy. The FDA completed its review of Osmol’s IND, notifying Osmol that our Phase 1 clinical study may proceed. In vivo and in vitro data support the development and effectiveness of OSM-0205 including: characterization of mechanism of efficacy, validation in mouse models of CIPN, and in vivo demonstration of no effect on chemotherapy efficacy. In addition, a limited clinical experience supports the therapeutic hypothesis. Finally, in vivo data support the potential for efficacy in a follow-on indication, chemotherapy-induced cognitive impairment (CICI). Market research with breast cancer specialists at leading US cancer centers confirmed the significant need for effective CIPN treatment, to prevent CIPN and allow for optimal chemotherapy treatment. In this same market research, payers covering 100M lives in the US confirmed the need for a preventative treatment and would reimburse it. Based on this market research, OSM-0205 peak sales for taxane-treated patients alone is projected to exceed $1.2B.

Location: K12

Founded in December 2020, HanchorBio is a clinical-stage biotech company with footprint spanning across multiple regions (USA, CHN, TWN). We specialize in developing novel, multi-targeting biomedicines through our “Fc-Based Designer Biologics” (FBDB) and “Shielded Designer ImmunoCytokine” (SDIC) platforms. Using proprietary protein engineering techniques, we have obtained an innate immunity engager (HCB101) that exhibits superior in vivo efficacy and marked safety profiles. These were fully demonstrated through in vivo efficacy testing of over 20 cancer models and two monkey toxicology studies. HCB101 is currently going through Phase I clinical trials. Our SDIC cytokine platform represents the most advanced version of guided immunocytokines that comprise all the desirable attributes such as superior safety features, outstanding in-vivo efficacy, favorable thermostability, and extended serum half-life. We have multiple SDIC programs in progress concurrently, covering indications in oncology and autoimmune diseases. As a spin-off from Henlius, HanchorBio’s colleagues possess a wide range of expertise and have over 10 years of experience in discovery research. We also recruit excellent scientists worldwide to achieve more diverse capabilities of innovation. This includes operations of an in-house animal facility with over 100 cancer models for in vivo testing. In addition, we have established process development (PD) capability to manage various aspects of upstream, downstream, analytical method developments, and up to 50L GLP toxicology material preparation. Due to this highly efficient, streamlined operation, we are able to advance pipeline programs in a rapid pace, obtaining our first IND clearance from the US FDA in 2.3 years since the company’s inception. Our ultimate goal is to overcome the limitations of the current checkpoint inhibitor approaches and lead the immune-based therapies into a new dimension.

Location: K12

Txinno Bioscience Inc. established in September 2020 with a vision to give hope and happiness to cancer patients and their family. Main Business Area is a dedicated company developing novel small molecule drugs for targeted therapy and immunotherapy to treat cancer patients. Txinno Bioscience is exclusively focused on developing innovative, small molecule anti-cancer drug candidates. We have 6 assets of various stages, among those, ENPP1 and ULK1 inhibitor are our representative pipelines. Txinno Bioscience is developing anti-cancer treatments focused on two intertwined aspects of physiology of tumor tissue. The first one is defined as tumor-intrinsic factors which are either genes or signaling pathways of tumor cells to directly control tumor cell proliferation or survival. Corresponding assets are ULK1 inhibitor, ‘Target S’ inhibitor, ‘Target I’ inhibitor and ‘Target Y’ inhibitor related to RAS signaling pathway. The other one is defined as tumor-extrinsic factors which are various signaling pathways operating in stromal cells other than tumor cells and promoting cancer cells to survive. Corresponding assets are ENPP1 inhibitor and ‘Target Z’ inhibitor controlling STING signaling pathway. In Txinno Bioscience, we developed two platform technologies to address these issues and facilitate our drug development process. 1) TxLFinder™ that can cultivate cancer cell spheroid and immune cells from PBMC in separate compartments of microplate wells. With immune cells appropriately stained for detection, the effect of drug treatment on infiltration of immune cells toward the spheroid can be measured. 2) TxTQuantifier™ is a co-culture system that are composed of spheroid from cancer cell line, isolated human immune cells, cancer-associated fibroblast, adipocytes and fabricated extracellular matrix to closely mimic actual human TME.

Location: K12

Myeloid Therapeutics is a clinical stage immunology company, engineering cutting-edge RNA technology to program immune cells to combat cancer and other deadly diseases. Myeloid is headquartered in Cambridge, MA.

Location: K12

Accession Therapeutics is developing a proprietary pipeline of highly targeted immuno-oncology products with a range of therapeutic payloads. The ideal immunotherapy is highly specific to a tumour, broad in action to kill all cancer cell variants, and potent in activating the full immune system arsenal locally.

Location: Room K12

VacV is a cancer immunotherapy company developing viral-based therapies for cancer. Our versatile technology uses a novel oncolytic Vaccinia virus and is designed to create efficacious and safe treatments. Our promising pipeline of easy-to-administer treatments includes features that offer significant advantages compared to existing treatment options.

Location: Room K1

Gain insights from leading pharma and venture investors on navigating the dealmaking landscape and standing out in the current climate. Discover strategies, trends, and key considerations for successful partnerships. Join this session to learn how to thrive in today's competitive environment and drive impactful collaborations.

Location: Room K1

Explore why AI is not just a trend but a transformative force shaping the future of healthcare and biopharma. Gain insights into its profound implications for research, development, and patient care.

Location: Room K1

Hear how AI algorithms are reshaping the landscape, accelerating the identification and development of novel therapeutics. Learn from industry experts about the latest advancements, challenges, and promising opportunities in this frontier of innovation.

Location: Room K1

Explore how AI-driven technologies are revolutionizing medical diagnostics, enhancing accuracy, efficiency, and patient outcomes. Gain valuable insights from experts on the latest developments, challenges, and future prospects in leveraging AI for diagnostic purposes.

Location: Exhibit Hall Stage

Explore the transformative impact of evolving pharmaceutical legislation on investor and company strategies within the life science ecosystem. Delve into the intricate interplay between regulatory changes, market dynamics, and strategic decision-making, as industry experts navigate the path forward amidst shifting landscapes and emerging opportunities.

Location: Exhibit Hall Stage

Join us for a fireside chat where experts assess the impact of US policies on the European life sciences ecosystem. Delve into the regulatory landscape, market dynamics, and strategic implications, exploring how transatlantic influences shape the future of biopharma innovation and collaboration.

Location: Room K2

We are a pharmaceutical company committed to research and development of medicines for patients around the world.

Location: Exhibit Hall Stage

This session will explore the transformative potential of intratumoral therapies, including local immune activators, oncolytic viruses and radioenhancers, in revolutionizing cancer treatment. As these novel treatments face unique challenges in drug delivery and clinical adoption, the role of venture capital investment becomes critical. Collaboration with small and medium-sized enterprises is essential to advance innovation, overcome barriers, and accelerate the development of intratumoral therapies. This discussion will emphasise how strategic investments and collaborations have been a springboard to drive growth in this emerging field and unlock the potential to transform the standard of care for cancer patients.

Location: Exhibit Hall Stage

Precision medicine represents a paradigm shift in healthcare, moving from a one-size-fits-all approach to personalized treatments based on an individual's genetic, environmental, and lifestyle factors. This session will explore the prospects of precision medicine, highlighting the technological, regulatory, and implementation challenges that must be overcome to integrate these advancements into the routine healthcare setting.

Location: Room K2

Big pharma’s ADC land grab has driven a multi-billion-dollar dealmaking frenzy. This session explains what the excitement is all about, providing insights into the current ADC landscape, latest innovations and challenges facing ADC development. Hear perspectives on the future of ADCs and their potential the reshape the paradigm of precision medicine.

Location: Room K2

Explore the burgeoning radioligand therapy landscape, with its multiple innovation areas and lucrative partnerships. Delve into the unique advantages of targeted radiotherapies, recent deals, and uncover the strategic opportunities that lie ahead.

Location: Room K2

Delve into the groundbreaking potential of cell and gene therapy and it’s potential to reshape healthcare as we know it. Explore the transformative impact of these therapies on disease treatment and prevention, challenging conventional medical paradigms. Discover how these innovative modalities are rewriting the rules of healthcare for a brighter future.

Cell and gene therapy: Insights

Location: Room K2

This session delves into the future of cardiometabolic therapy. As the buzz around GLP-1 receptor agonist-based drugs stabilises, the sector is already on the lookout for novel cardiometabolic treatment modalities. Dive into the collaborations focusing on cardiometabolic therapies, the implications and partnering strategies, in the evolving landscape of cardiometabolic care.

Location: Exhibit Hall Stage

The upcoming EHDS2 regulation, set to replace national laws that control healthcare data usage for research within the EU, aims to standardize cross-border access to healthcare data across the EU for both academic and commercial purposes. Accessing data remains a complex process due to GDPR legislation, involving multiple steps such as data availability queries, processing data access applications, and releasing pseudonymized data for Secure Processing Environments (SPE), federated data analysis or as anonymised format.

For data sources, this regulation requires providing data descriptions to the HealthData@EU portal, enabling researchers to find suitable data sources for their projects, as well as to reply data queries. As data sources become more accessible, the volume of data availability and data access applications is expected to increase significantly. Therefore, it is crucial to automate and optimize current, often manual, processes to meet the EHDS-defined time limits for responses and to keep track of work hours and other resources used in project level.

BC Platforms has developed various AI-enhanced software tools to support data sources, such as university hospitals and National Contact Points, in complying with the forthcoming EHDS requirements e.g. for meta data descriptions and data quality labelling, complex feasibility queries, data access application and approval handling, data anonymisation and data release to SPEs. For researchers and AI model developers, BC Platforms offers advanced data analysis software operating within a Secure Processing Environment (SPE), capable of tracking hardware or cloud costs by project.

BC Platforms collaborates with major healthcare data integrator companies to deliver solutions ranging from individual hospital implementations to national-scale systems.

Location: Exhibit Hall Stage

In the European Union (EU), medicines are authorized centrally, but reimbursement is carried out at the national level: the EU member states conduct national assessment procedures for this purpose, known as health technology assessments (HTAs). Harmonization of these procedures is one of the most important innovations in the regulatory framework for medicines in Europe. From January 2025, a common clinical assessment will come into force in the EU. This will be introduced gradually, starting with cancer medicines (including orphan oncology drugs) and ATMPs. A whole series of important EU regulations came into force in 2024. Currently, national regulations are being adapted to the new European procedure in the EU member states. And now, in the fall of 2024, many details regarding the implementation and execution of the new procedure are clarified. This panel will discuss how small and large biopharmaceutical companies need to adapt to the new procedure to reach Europe’s patients quickly and successfully with their innovative therapies.